NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT05154994 2026-01-27
RESOLVE
University of Utah
Phase 1 Active not recruiting
NCT03871036 2025-03-06
ICRA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03317158 2025-01-30
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04637594 2025-01-15
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04543110 2023-03-23
RADIANT
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT04579133 2021-06-16
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
Phase 2 Terminated